Healthcare
Live Price
Offline$34.14
+5.11% today
1Y Change
+98.09%
Window
Jun 25, 2025 โ Jun 23, 2026
Coverage: 249 bars ยท Jun 25, 2025 โ Jun 23, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Beam Therapeutics Inc. (BEAM) is a Healthcare stock with a market cap of $2.97B. The stock last traded around $34.14 and up 98.1% across the available one-year price window (Jun 25, 2025 โ Jun 23, 2026). Baseline metrics include revenue growth of +120.0%, EPS growth of +82.3%, a dividend yield of 0.0%. What stands out right now is revenue +120.0%, EPS +82.3%, free cash flow -1.1% with operating margin -274.6% and ROIC -27.4%. Valuation already assumes a fairly strong business story at price/sales 21.2. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines BEAM price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+120.0% vs +7.6% peer median
Operating Margin
Below sector median
-274.6% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 5, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +120.0% and EPS at +82.3%, with operating margin around -274.6%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -2.5% over the next 5 trading days and finished higher after 1 of those reports.
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 5, 2026 | โ | +11.9% | +9.3% | +2.2% |
2026 Feb 24, 2026 | +91.2% | -8.3% | -15.7% | -25.8% |
2025 Nov 4, 2025 | -12.2% | +1.5% | -1.1% | +17.6% |
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
BEAM
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
BEAM Max Drawdown
-38.15%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Uses the longest available daily history for BEAM and SPY.
Company Overview
Beam Therapeutics Inc.
Valuation, growth, profitability, and balance sheet signals.
Company announcements and filings-style updates.
Next Step
After the overview, the strongest next step is usually chart context or a tighter compare set.